Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
(The author is a Reuters Breakingviews columnist. The opinions expressed are her own.) By Katrina Hamlin HONG KONG, Oct 16 (Reuters Breakingviews) — Long gone are the days when Big Pharma scoffed at the reliability of China's clinical trials. The world's biggest drugmakers are increasingly looking to biotech researcher
Bernstein cut its target price on AstraZeneca to 198 pounds from 200 pounds and kept a positive view on the drugmaker’s pipeline. Shares were up 1% at 120.80 pounds.
Insmed (NASDAQ: INSM ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Insmed reported strong
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
EU panel recommends approval for AstraZeneca's breast cancer treatment camizestrant, a potential competitor to Pfizer's Ibrance